Unintended consequences--the cost of preventing... [N Engl J Med. 2011] - PubMed

Save items

loading

Related citations in PubMed

Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate). [Obstet Gynecol. 2011]
Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Cohen AW, Copel JA, Macones GA, Menard MK, Riley L, Saade GR. Obstet Gynecol. 2011 Jun; 117(6):1408-12.
17-α hydroxyprogesterone caproate for the prevention of preterm birth. [Womens Health (Lond Engl). 2012]
17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S, Roman AS. Womens Health (Lond Engl). 2012 Jan; 8(1):21-30.
17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. [Obstet Gynecol. 2006]
17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO, Stamilio DM, Macones GA, Polsky D. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):492-9.
Review 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. [Reprod Toxicol. 2012]
Review 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P, Stahl B, Klinger G. Reprod Toxicol. 2012 Jan; 33(1):15-9. Epub 2011 Nov 20.
Review Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. [Am J Obstet Gynecol. 2007]
Review Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
Bailit JL, Votruba ME. Am J Obstet Gynecol. 2007 Mar; 196(3):219.e1-7.

See reviews... See all...

Cited by 3 PubMed Central articles

Innovation flourishes at a time of benefit coverage uncertainty. [Biotechnol Healthc. 2012]
Innovation flourishes at a time of benefit coverage uncertainty.
Vogenberg FR. Biotechnol Healthc. 2012 Fall; 9(3):4.
Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question. [P T. 2012]
Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.
Patel Y, Rumore MM. P T. 2012 Jul; 37(7):405-11.
Regulators place spotlight on drug prices. [Biotechnol Healthc. 2011]
Regulators place spotlight on drug prices.
Carroll J. Biotechnol Healthc. 2011 Summer; 8(2):8-9.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Unintended consequences--the cost of preventing preterm births after FDA approva...
Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
N Engl J Med. 2011 May 5 ;364(18):1689-91. doi: 10.1056/NEJMp1102796. Epub 2011 Mar 16 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.

Source

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information